Multifocal IOLs as presbyopia treatment

Article

Implanting a multifocal intraocular lens (IOL) into the non-dominant eye is a promising treatment for presbyopic emmetropic patients, according to a study published in the February 2008 issue of Spektrum der Augenheilkunde.

Implanting a multifocal intraocular lens (IOL) into the non-dominant eye is a promising treatment for presbyopic emmetropic patients, according to a study published in the February 2008 issue of Spektrum der Augenheilkunde.

Dr Thomas Neuhann of the Augenklinik am Marienplatz, Munich, Germany evaluated monocular implantation of a multifocal diffractive apodized IOL (SN60D3, AcrySof ReSTOR Natural; Alcon) as a rehabilitative treatment for emmetropic and presbyopic patients (n=24).

Six months after unilateral implantation, all patients were found to have bilateral uncorrected near vision of 20/30; 83% of patients recorded uncorrected distance vision of 20/20. Half of patients remained spectacle-dependent for intermediate vision. A questionnaire determined overall patient satisfaction of 79% for near, intermediate and distance vision. One patient requested IOL implantation in the second eye.

Dr Neuhann concluded that unilateral IOL implantation offers a viable treatment option for sufferers of emmetropia and presbyopia.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.